Searched for
THERAPY FOOTPRINT
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- Infosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform globalPrecision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Two separate venues for pharma industry expos in Delhi-NCRCPHI India and PMEC India are expanding their pharmaceutical expos to two venues in Delhi-NCR. This move aims to support the rapid growth o...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- Johnson & Johnson to invest $1 billion in new Pennsylvania plant amid US manufacturing pushIn March, the company announced a plan to invest more than $55 billion through early 2029 to build manufacturing facilities and research ...
- Lupin signs supply deal to launch antidepressant in CanadaDrug firm Lupin has partnered with Spektus Pharma. They will commercialise the antidepressant DeslaFlex in Canada. This collaboration combi...
- Novartis bets big on India; looks to grow beyond cost arbitrage to high-value innovationNovartis is significantly expanding its biomedical research and drug development operations in India, positioning it as a key global hub ou...
- Venus Remedies gets new market authorisations for drugs in VietnamPharma major Venus Remedies has received new marketing authorisations in Vietnam for its drugs Methotrexate, Cefuroxime, and Irinotecan. Th...
- Motilal Oswal initiates coverage on Mankind Pharma with target price of Rs 2,650Motilal Oswal initiated coverage on Mankind Pharma with a 'buy' call and target price of Rs 2,650. The company's disruptive strategy in est...
- Value Pick: Anand Rathi has buy on Cipla, target price Rs 738The brokerage believes that with healthy earnings growth and core ROCE expansion over FY20-22e, Cipla’s valuations are likely to witness re...
- ET Q&A: Need Government investments to develop cure for epidemics like Covid-19In the absence of sustained investments by government, the cure for epidemics such as Covid-19 becomes a challenge, Novartis global CEO Vas...
- Eyeing over 80% sales from US, India, Europe by 2021: GlenmarkAs part of its medium term strategy, the company is also looking at increasing presence in complex generics, Glenmark said in a presentatio...
- Biomarkers of cognitive impairment found in HIV patients: StudyNew York, Sep 25 (IANS) Using reliable biomarkers, researchers have found a unique epigenetic footprint which offers them insight into how ...
- Glenmark climbs 3% on bullish management guidanceShares of Glenmark gained about 3 per cent in Wednesday's trade after the company provided a bullish guidance of 18-20 per cent growing in ...
- Dr Reddy’s agrees to buy UCB business in India for Rs 800 croreThe deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement ...
- Sun Pharma-Ranbaxy combine creates a new market leader in Indian marketThe proposed new entity would unseat Abbott from the top position, which holds current market share of 6.5%, according to research firm Aio...
- Baxter enhances renal therapies portfolio with acquisition of GambroThe transaction will provide a number of long-term growth opportunities for Baxter around the world.
Load More
